Sbi Securities Co., Ltd. Sage Therapeutics, Inc. Transaction History
Sbi Securities Co., Ltd.
- $3.48 Trillion
- Q2 2025
A detailed history of Sbi Securities Co., Ltd. transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Sbi Securities Co., Ltd. holds 3 shares of SAGE stock, worth $26. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3
Previous 5
40.0%
Holding current value
$26
Previous $40,000
32.5%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding SAGE
# of Institutions
221Shares Held
49.6MCall Options Held
241KPut Options Held
587K-
Black Rock Inc. New York, NY5.22MShares$45.3 Million0.0% of portfolio
-
Madison Avenue Partners, LP New York, NY4.48MShares$38.9 Million4.6% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.27MShares$28.3 Million0.0% of portfolio
-
Tig Advisors, LLC New York, NY2.73MShares$23.7 Million1.36% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY2.09MShares$18.1 Million0.02% of portfolio
About Sage Therapeutics, Inc.
- Ticker SAGE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,422,300
- Market Cap $516M
- Description
- Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...